{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:46:25Z","timestamp":1771991185255,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dr. Willmar Schwabe GmbH & Co. KG","award":["n.a."],"award-info":[{"award-number":["n.a."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00406-017-0852-4","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T10:50:30Z","timestamp":1510915830000},"page":"183-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials"],"prefix":"10.1007","volume":"269","author":[{"given":"Hans-J\u00fcrgen","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Volz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Dienel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Schl\u00e4fke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-191X","authenticated-orcid":false,"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"852_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-244X-14-128","volume":"14","author":"H Haller","year":"2014","unstructured":"Haller H, Cramer H, Lauche R, Gass F, Dobos GJ (2014) The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. BMC Psychiatry 14:128. \n                    https:\/\/doi.org\/10.1186\/1471-244X-14-128","journal-title":"BMC Psychiatry"},{"issue":"12","key":"852_CR2","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1176\/appi.ps.57.12.1719","volume":"57","author":"CI Cohen","year":"2006","unstructured":"Cohen CI, Magai C, Yaffee R, Walcott-Brown L (2006) The prevalence of anxiety and associated factors in a multiracial sample of older adults. Psychiatr Serv 57(12):1719\u20131725. \n                    https:\/\/doi.org\/10.1176\/appi.ps.57.12.1719","journal-title":"Psychiatr Serv"},{"issue":"4","key":"852_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/da.10065","volume":"16","author":"HU Wittchen","year":"2002","unstructured":"Wittchen HU (2002) Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16(4):162\u2013171. \n                    https:\/\/doi.org\/10.1002\/da.10065","journal-title":"Depress Anxiety"},{"issue":"12","key":"852_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/NMD.0b013e3181c29992","volume":"197","author":"AE Lawrence","year":"2009","unstructured":"Lawrence AE, Brown TA (2009) Differentiating generalized anxiety disorder from anxiety disorder not otherwise specified. J Nerv Ment Dis 197(12):879\u2013886. \n                    https:\/\/doi.org\/10.1097\/NMD.0b013e3181c29992","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"852_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/da.22021","volume":"30","author":"J Karsten","year":"2013","unstructured":"Karsten J, Penninx BW, Verboom CE, Nolen WA, Hartman CA (2013) Course and risk factors of functional impairment in subthreshold depression and anxiety. Depress Anxiety 30(4):386\u2013394. \n                    https:\/\/doi.org\/10.1002\/da.22021","journal-title":"Depress Anxiety"},{"issue":"4","key":"852_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0005-7967(02)00130-4","volume":"41","author":"GJ Diefenbach","year":"2003","unstructured":"Diefenbach GJ, Hopko DR, Feigon S, Stanley MA, Novy DM, Beck JG, Averill PM (2003) \u2018Minor GAD\u2019: characteristics of subsyndromal GAD in older adults. Behav Res Ther 41(4):481\u2013487","journal-title":"Behav Res Ther"},{"issue":"3","key":"852_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10880-011-9248-1","volume":"18","author":"SJ Kertz","year":"2011","unstructured":"Kertz SJ, Woodruff-Borden J (2011) Human and economic burden of GAD, subthreshold GAD, and worry in a primary care sample. J Clin Psychol Med Settings 18(3):281\u2013290. \n                    https:\/\/doi.org\/10.1007\/s10880-011-9248-1","journal-title":"J Clin Psychol Med Settings"},{"key":"852_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.janxdis.2015.05.011","volume":"34","author":"N Kanuri","year":"2015","unstructured":"Kanuri N, Taylor CB, Cohen JM, Newman MG (2015) Classification models for subthreshold generalized anxiety disorder in a college population: implications for prevention. J Anxiety Disord 34:43\u201352. \n                    https:\/\/doi.org\/10.1016\/j.janxdis.2015.05.011","journal-title":"J Anxiety Disord"},{"issue":"3","key":"852_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1192\/bjp.bp.110.080572","volume":"198","author":"J Karsten","year":"2011","unstructured":"Karsten J, Hartman CA, Smit JH, Zitman FG, Beekman AT, Cuijpers P, van der Does AJ, Ormel J, Nolen WA, Penninx BW (2011) Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2\u00a0years. Br J Psychiatry 198(3):206\u2013212. \n                    https:\/\/doi.org\/10.1192\/bjp.bp.110.080572","journal-title":"Br J Psychiatry"},{"issue":"4","key":"852_CR10","doi-asserted-by":"publisher","first-page":"e59998","DOI":"10.1371\/journal.pone.0059998","volume":"8","author":"AM Schuwald","year":"2013","unstructured":"Schuwald AM, N\u00f6ldner M, Wilmes T, Klugbauer N, Leuner K, M\u00fcller WE (2013) Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS One 8(4):e59998. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0059998","journal-title":"PLoS One"},{"issue":"1","key":"852_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1037\/a0026517","volume":"12","author":"AB Satpute","year":"2012","unstructured":"Satpute AB, Mumford JA, Naliboff BD, Poldrack RA (2012) Human anterior and posterior hippocampus respond distinctly to state and trait anxiety. Emotion 12(1):58\u201368. \n                    https:\/\/doi.org\/10.1037\/a0026517","journal-title":"Emotion"},{"key":"852_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu063","author":"P Baldinger","year":"2014","unstructured":"Baldinger P, Hoflich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Lanzenberger R, Kasper S (2014) Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol. \n                    https:\/\/doi.org\/10.1093\/ijnp\/pyu063","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"852_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1017\/S1461145714000017","volume":"17","author":"S Kasper","year":"2014","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Schl\u00e4fke S, Dienel A (2014) Lavender oil preparation Silexan is effective in generalized anxiety disorder\u2014a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 17(6):859\u2013869. \n                    https:\/\/doi.org\/10.1017\/S1461145714000017","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"852_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/YIC.0b013e32833b3242","volume":"25","author":"S Kasper","year":"2010","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz HP, M\u00f6ller HJ, Dienel A, Schl\u00e4fke S (2010) Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of \u2018subsyndromal\u2019 anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 25(6):277\u2013287. \n                    https:\/\/doi.org\/10.1097\/YIC.0b013e32833b3242","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"852_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.euroneuro.2015.12.002","volume":"26","author":"S Kasper","year":"2016","unstructured":"Kasper S, Volz HP, Dienel A, Schlafke S (2016) Efficacy of Silexan in mixed anxiety-depression\u2014a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 26(2):331\u2013340. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2015.12.002","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"852_CR16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.euroneuro.2015.07.024","volume":"25","author":"S Kasper","year":"2015","unstructured":"Kasper S, Anghelescu I, Dienel A (2015) Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep\u2014a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 25(11):1960\u20131967. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2015.07.024","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8\u20139","key":"852_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.phymed.2012.02.020","volume":"19","author":"B Uehleke","year":"2012","unstructured":"Uehleke B, Schaper S, Dienel A, Schl\u00e4fke S, Stange R (2012) Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. Phytomedicine 19(8\u20139):665\u2013671. \n                    https:\/\/doi.org\/10.1016\/j.phymed.2012.02.020","journal-title":"Phytomedicine"},{"issue":"2","key":"852_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.phymed.2009.10.006","volume":"17","author":"H Woelk","year":"2010","unstructured":"Woelk H, Schl\u00e4fke S (2010) A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 17(2):94\u201399","journal-title":"Phytomedicine"},{"key":"852_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2017.1301488","author":"M Gastpar","year":"2017","unstructured":"Gastpar M, M\u00fcller WE, Volz HP, M\u00f6ller HJ, Schl\u00e4fke S, Dienel A, Kasper S (2017) Silexan does not cause withdrawal symptoms even when abruptly discontinued. Int J Psychiatry Clin Pract. \n                    https:\/\/doi.org\/10.1080\/13651501.2017.1301488","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"3\u20134","key":"852_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10354-012-0164-2","volume":"163","author":"V Kumar","year":"2013","unstructured":"Kumar V (2013) Characterization of anxiolytic and neuropharmacological activities of Silexan. Wien Med Wochenschr 163(3\u20134):89\u201394. \n                    https:\/\/doi.org\/10.1007\/s10354-012-0164-2","journal-title":"Wien Med Wochenschr"},{"issue":"4","key":"852_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40268-014-0065-5","volume":"14","author":"D Heger-Mahn","year":"2014","unstructured":"Heger-Mahn D, Pabst G, Dienel A, Schlafke S, Klipping C (2014) No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol\/levonorgestrel combination. Drugs R&D 14(4):265\u2013272. \n                    https:\/\/doi.org\/10.1007\/s40268-014-0065-5","journal-title":"Drugs R&D"},{"issue":"10","key":"852_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s00101-011-1916-x","volume":"60","author":"SO Decker","year":"2011","unstructured":"Decker SO, Polarz H (2011) Silexan und Narkose: fallbericht und M\u00f6glichkeiten des pr\u00e4- sowie perioperativen Managements. Anaesthesist 60(10):946\u2013949. \n                    https:\/\/doi.org\/10.1007\/s00101-011-1916-x","journal-title":"Anaesthesist"},{"issue":"1","key":"852_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/JCP.0000000000000615","volume":"37","author":"MB Generoso","year":"2017","unstructured":"Generoso MB, Soares A, Taiar IT, Cordeiro Q, Shiozawa P (2017) Lavender oil preparation (Silexan) for treating anxiety: an updated meta-analysis. J Clin Psychopharmacol 37(1):115\u2013117. \n                    https:\/\/doi.org\/10.1097\/JCP.0000000000000615","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 1","key":"852_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/13651501.2013.813555","volume":"17","author":"S Kasper","year":"2013","unstructured":"Kasper S (2013) An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. Int J Psychiatry Clin Pract 17(Suppl 1):15\u201322. \n                    https:\/\/doi.org\/10.3109\/13651501.2013.813555","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"21\u201322","key":"852_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10354-010-0845-7","volume":"160","author":"S Kasper","year":"2010","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz HP, M\u00f6ller HJ, Dienel A, Schl\u00e4fke S (2010) Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder\u2014evidence from clinical trials. Wien Med Wochenschr 160(21\u201322):547\u2013556. \n                    https:\/\/doi.org\/10.1007\/s10354-010-0845-7","journal-title":"Wien Med Wochenschr"},{"issue":"3","key":"852_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1055\/s-0034-1399243","volume":"83","author":"A Quante","year":"2015","unstructured":"Quante A (2015) Akute pharmakologische Therapieoptionen von \u00e4ngstlicher Symptomatik bei Patienten mit Depression. Fortschr Neurol Psychiatr 83(3):142\u2013148. \n                    https:\/\/doi.org\/10.1055\/s-0034-1399243","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"1","key":"852_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","volume":"14","author":"W Maier","year":"1988","unstructured":"Maier W, Buller R, Philipp M, Heuser I (1988) The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14(1):61\u201368","journal-title":"J Affect Disord"},{"key":"852_CR28","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. \n                    https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"852_CR29","doi-asserted-by":"publisher","first-page":"c221","DOI":"10.1136\/bmj.c221","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340:c221. \n                    https:\/\/doi.org\/10.1136\/bmj.c221","journal-title":"BMJ"},{"issue":"5","key":"852_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/sim.7141","volume":"36","author":"DL Burke","year":"2017","unstructured":"Burke DL, Ensor J, Riley RD (2017) Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 36(5):855\u2013875. \n                    https:\/\/doi.org\/10.1002\/sim.7141","journal-title":"Stat Med"},{"key":"852_CR31","unstructured":"Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration. \n                    www.handbook.cochrane.org\n                    \n                  . Accessed 13 Apr 2016"},{"issue":"10 Suppl 12","key":"852_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S1092852900025815","volume":"11","author":"B Bandelow","year":"2006","unstructured":"Bandelow B (2006) Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr 11(10 Suppl 12):21\u201328","journal-title":"CNS Spectr"},{"issue":"8","key":"852_CR33","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0269881107076996","volume":"21","author":"RB Hidalgo","year":"2007","unstructured":"Hidalgo RB, Tupler LA, Davidson JR (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21(8):864\u2013872. \n                    https:\/\/doi.org\/10.1177\/0269881107076996","journal-title":"J Psychopharmacol"},{"key":"852_CR34","doi-asserted-by":"publisher","first-page":"CD008120","DOI":"10.1002\/14651858.CD008120.pub2","volume":"12","author":"AM Depping","year":"2010","unstructured":"Depping AM, Komossa K, Kissling W, Leucht S (2010) Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 12:CD008120. \n                    https:\/\/doi.org\/10.1002\/14651858.CD008120.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"852_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ajp.2017.01.016","volume":"26","author":"N Zareifopoulos","year":"2017","unstructured":"Zareifopoulos N, Dylja I (2017) Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis. Asian J Psychiatr 26:115\u2013122. \n                    https:\/\/doi.org\/10.1016\/j.ajp.2017.01.016","journal-title":"Asian J Psychiatr"},{"issue":"6","key":"852_CR36","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.euroneuro.2016.02.013","volume":"26","author":"DS Baldwin","year":"2016","unstructured":"Baldwin DS, Asakura S, Koyama T, Hayano T, Hagino A, Reines E, Larsen K (2016) Efficacy of escitalopram in the treatment of social anxiety disorder: a meta-analysis versus placebo. Eur Neuropsychopharmacol 26(6):1062\u20131069. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2016.02.013","journal-title":"Eur Neuropsychopharmacol"},{"key":"852_CR37","doi-asserted-by":"publisher","first-page":"003592","DOI":"10.1002\/14651858.CD003592","volume":"2","author":"F Kapczinski","year":"2003","unstructured":"Kapczinski F, Lima MS, Souza JS, Schmitt R (2003) Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2:003592. \n                    https:\/\/doi.org\/10.1002\/14651858.CD003592","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"852_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/13651501.2012.667114","volume":"16","author":"B Bandelow","year":"2012","unstructured":"Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Moller HJ, Care WTFoMDiP, WFSBP Task Force on Anxiety Disorders, O. C. D., Ptsd (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16(2):77\u201384. \n                    https:\/\/doi.org\/10.3109\/13651501.2012.667114","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"2","key":"852_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/070674370004500207","volume":"45","author":"MM Ohayon","year":"2000","unstructured":"Ohayon MM, Shapiro CM, Kennedy SH (2000) Differentiating DSM-IV anxiety and depressive disorders in the general population: comorbidity and treatment consequences. Can J Psychiatry 45(2):166\u2013172","journal-title":"Can J Psychiatry"},{"key":"852_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4236\/ojpsych.2015.53032","volume":"5","author":"W Dimpfel","year":"2015","unstructured":"Dimpfel W, Wedekind W, Dienel A (2015) Cerebral bioavailability of silexan\u2014a quantitative EEG study in healthy volunteers. Open J Psychiatr 5:285\u2013297. \n                    https:\/\/doi.org\/10.4236\/ojpsych.2015.53032","journal-title":"Open J Psychiatr"},{"issue":"1","key":"852_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/PCC.v03n0105","volume":"3","author":"JM Ferguson","year":"2001","unstructured":"Ferguson JM (2001) SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3(1):22\u201327","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"5","key":"852_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2165\/00002018-199410050-00002","volume":"10","author":"FE Simons","year":"1994","unstructured":"Simons FE (1994) H1-receptor antagonists. Comparative tolerability and safety. Drug Saf 10(5):350\u2013380","journal-title":"Drug Saf"},{"key":"852_CR43","unstructured":"European Medicines Agency (2015) New restrictions to minimise the risks of effects on heart rhythm with hydroxyzine-containing medicines. EMA\/149624\/2015, 27 March 2015"},{"issue":"5","key":"852_CR44","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cpr.2004.06.001","volume":"24","author":"KA Collins","year":"2004","unstructured":"Collins KA, Westra HA, Dozois DJ, Burns DD (2004) Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care. Clin Psychol Rev 24(5):583\u2013616. \n                    https:\/\/doi.org\/10.1016\/j.cpr.2004.06.001","journal-title":"Clin Psychol Rev"},{"issue":"9","key":"852_CR45","first-page":"1305","volume":"4","author":"WN Setzer","year":"2009","unstructured":"Setzer WN (2009) Essential oils and anxiolytic aromatherapy. Nat Prod Commun 4(9):1305\u20131316","journal-title":"Nat Prod Commun"},{"issue":"37","key":"852_CR46","first-page":"55","volume":"140","author":"G Binder","year":"2000","unstructured":"Binder G, K\u00f6nig WA (2000) \u00c4therische \u00d6le - Untersuchung zur Deklaration und Qualit\u00e4t ausgew\u00e4hlter Pr\u00e4parate. Dtsch Apoth Ztg 140(37):55\u201362","journal-title":"Dtsch Apoth Ztg"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-017-0852-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-017-0852-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-017-0852-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T13:19:04Z","timestamp":1572009544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-017-0852-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s00406-017-0852-4","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,17]]},"assertion":[{"value":"11 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Hans-J\u00fcrgen M\u00f6ller has received grant\/research support, consulting fees and honoraria within the last years from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, MSD, Novartis, Organon, Otsuka, Pfizer, Schwabe, Sepracor, Servier, and Wyeth. Hans-Peter Volz has served as a consultant or on advisory boards for Astra\/Zeneca, Eli Lilly, Lundbeck, Pfizer, Schwabe, Janssen, Otsuka, Merz, Wyeth, neuraxpharm and has served on speakers\u2019 bureaus for Astra\/Zeneca, Eli Lilly, Lundbeck, Schwabe, Janssen, Merz, Wyeth, Lichtwer, Steigerwald, Hormosan, neuraxpharm and Bristol-Myers Squibb. Angelika Dienel and Sandra Schl\u00e4fke are employees of Dr. Willmar Schwabe GmbH & Co. KG, manufacturer of Silexan. Siegfried Kasper received grants\/research support, consulting fees and\/or honoraria within the last 3\u00a0years from Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, KRKA-Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre, Schwabe and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}